Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial
Results of a Phase 3 randomised, double-blind, placebo-controlled trial to investigate the efficacy of cannabidiol (CBD) as add-on therapy for drop seizures (sudden falls due to seizures) in patients with treatment-resistant Lennox-Gastaut syndrome. After a 2 week dose escalation period, 171 patients across 24 clinical sites began a 12 week dosing period of 20mg/kg/day; administered as two equally divided doses morning and evening. Patients who completed treatment were eligible to enrol in an open-label extension trial.
RESULTS:
72 patients in the CBD group and 84 patients in the placebo group completed the study.
A higher occurrence of somnolence was observed in patients on antiepileptic drug regimens that included clobazam than those that did not include clobazam, or were in the placebo group.
Source: Centre for Medicinal Cannabis Research and Innovation
A systematic review and meta-analysis on the efficacy, tolerability, and safety of cannabinoids in palliative medicine.